Covered Call Analyzer AGGRESSIVE "STOCKS-TO-CONSIDER"
|
Company Name |
Stock Symbol |
Stock Price |
# of shares |
Total Cost* |
Option Symbol |
May Option Price |
Income from sale* |
Strike Price |
Projected return if Called after one month* |
Actual $ return* |
Actual % Return* |
| Amlin Pharm. | AMLN | $16.12 | 400 | $9,692 | UMQEE | $0.65 | $370 | 25 | 57% | +$4,430 | +46% |
| Comments: |
Not called. Sold Jun20 at 1.20. Not called. All positions sold at $21.72 to close out position. |
||||||||||
| IGEN Intl. | IGEN | $34.07 | 200 | $6,834 | GQEU | $2.00 | $380 | 37.5 | 15% | +$546 | +8% |
| Comments: |
Not called. Sold Jun37.5 at 2.25. Not called. Sold all shares at $32.75 to close out position. |
||||||||||
| ISS Group | ISSX | $11.73 | 800 | $9,404 | ISUEV | $0.75 | $580 | 12.5 | 12% | +$1,176 | +12% |
| Comments: |
Called. |
||||||||||
| Delta Airlines | DAL | $11.65 | 800 | $9,340 | DALEV | $0.60 | $460 | 12.5 | 12% | +$1,120 | +12% |
| Comments: |
Called. |
||||||||||
| Genesis Micorchip | GNSS | $13.92 | 700 | $9,764 | QFEEC | $0.60 | $400 | 15 | 11% | +$1,136 | +11% |
| Comments: |
Called. |
||||||||||
| IGEN Intl. | IGEN | $34.07 | 200 | $6,834 | GQEG | $2.95 | $570 | 35 | 10% | +$736 | +10% |
| Comments: |
Called. |
||||||||||
| Broadcom, Inc. | BRCM | $16.52 | 600 | $9,932 | RCQEW | $0.75 | $430 | 17.5 | 10% | +$998 | +10% |
| Comments: |
Called. |
||||||||||
| Noven Pharm. | NOVN | $14.05 | 700 | $9,855 | NPQEC | $0.50 | $330 | 15 | 10% | ($1,272) | -13% |
| Comments: |
Exercised get-out price at $11.94 after buying back calls at 0.15. |
||||||||||
| Fairchild Semi. | FCS | $11.88 | 800 | $9,524 | FCSEV | $0.50 | $380 | 12.5 | 9% | +$856 | +9% |
| Comments: |
Called. |
||||||||||
| ICOS Corp. | ICOS | $22.00 | 400 | $8,820 | IIQEX | $1.25 | $480 | 22.5 | 6% | +$660 | +6% |
| Comments: |
Called. |
||||||||||
|
All positions closed out with portfolio value up +$10,387. |
|||||||||||
*After the effect of all commissions.
The stocks listed above are for illustrative and educational purposes only and should not be construed as an endorsement, recommendation, or solicitation to buy or sell any particular security.